Epidemiology of exacerbations in chronic obstructive pulmonary disease

Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Volumn , Issue , 2003, Pages 5-11

  Vestbo, JØrgen ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864989108     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (30)

1. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117:398–401S.
2. Fletcher CM, Elmes PC, Fairbarn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959; 3:257–266.
3. Fairbarn AS, Wood CH, Fletcher CM. Variability in answers to a questionnaire on respiratory symptoms. Br J Prev Soc Med 1959; 13:175–193.
4. Fletcher CM, Peto R, Tinker CM, Speizer FE. The Natural History of Chronic Bronchitis and Emphysema. Oxford: Oxford University Press, 1976.
5. World Health Organization. Methods for cohort studies of chronic airflow limitation. Copenhagen: WHO Regional Office for Europe, 1982.
6. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196–204.
7. Pauwels R, Buist A, Calverley P, Jenkins C, Hurd S. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI=WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163:1256–1276.
8. British Thoracic Society. The Burden of Lung Disease. London: British Thoracic Society, 2001.
9. The Danish National Board of Health, www.sst.dk. Accessed December 10, 2001.
10. Vestbo J, Rasmussen FV. Respiratory symptoms and FEV1 as predictors of hospitalization and medication in the following 12 years due to respiratory disease. Eur Respir J 1989; 2:710–715.
11. Vestbo J, Prescott E, Lange P, The Copenhagen City Heart Study Group. Association of chronic mucus hypersecretion with FEV1 decline and COPD morbidity. Am J Respir Crit Care Med 1996; 153:1530–1535.
12. Prescott E, Bjerg AM, Andersen PK, Lange P, Vestbo J. Gender differences in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. Eur Respir J 1997; 10:822–827.
13. Prescott E, Lange P, Vestbo J, The Copenhagen City Heart Study Group. Socioeconomic status, lung function, and admission to hospital for COPD. Results from the Copenhagen City Heart Study. Eur Respir J 1999; 13:1109–1114.
14. Garcia-Aymerich J, Monso E, Marrades RM, Escarrabill J, Félez MA, Sunyer J, Anto J, The EFRAM investigators. Risk factors for hospitalisation for a chronic obstructive pulmonary disease exacernation. Am J Respir Crit Care Med 2001; 164:1002–1007.
15. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:580–584.
16. Miravitlles M, Guerrero T, Mayordomo C, Sanchez-Agudo L, Nicolau F, Segu JL. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respiration 2000; 67:495–501.
17. Osman LM, Godden DJ, Friend JAR, Legge JS, Douglas JG. Quality of life and hospital readmission in patients with chronic obstructive pulmonary disease. Thorax 1997; 52:67–71.
18. Decramer M, Gosselink R, Troosters T, Vershueren M, Evers G. Muscle weakness is related to utilization of health care resources in COPD. Eur Respir J 1997; 10:417–423.
19. Jarad NA, Wedzicha JA, Burge PS, Calverley PMA for the ISOLDE study group. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir Med 1999; 93:161–166.
20. O’Brien A, Russo-Magno P, Karki A, Hiranniramd S, Hardin M, Kaszuba M, Sherman C, Rounds S. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med 2001; 164:365–371.
21. Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17:982–994.
22. Sunyer J. Urban air pollution and chronic obstructive pulmonary disease: a review. Eur Respir J 2001; 17:1024–1033.
23. Seemungal TAR, Donaldson G, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1418–1422.
24. Wedzicha JA. Mechanisms of exacerbations. In: Chadwick D, Goode JA, eds. Chronic Obstructive Pulmonary Disease: Pathogenesis to Treatment. London: Novartis Foundation, 2001.
25. Seemungal T, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1608–1613.
26. Paggiaro PL, Dahle R, Bakran I, Filth L, Hollingworth K, Efthimiou J, on behalf of the international COPD study group. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351:773–780.
27. Vestbo J, Sørensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease—a randomised, controlled trial. Lancet 1999; 353:1819–1823.
28. Pauwels RA, Lofdahl C-G, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue to smoke. N Engl J Med 1999; 340:1948–1953.
29. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double-blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease; the ISOLDE trial. Br Med J 2000; 320:1297–1303.
30. The Lung Health Study Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343:1902–1909.